Autonomix Medical Appoints New CMO, Director

TL;DR

Autonomix Medical beefs up leadership with a new CMO and board member.

AI Summary

Autonomix Medical, Inc. announced on June 21, 2024, the appointment of Dr. David L. Bear as Chief Medical Officer and the election of Ms. Sarah P. Empey to its Board of Directors. The company also disclosed compensatory arrangements for its officers, though specific dollar amounts for these arrangements were not detailed in this filing.

Why It Matters

These appointments signal potential strategic shifts and leadership changes within Autonomix Medical, which could impact the company's future direction and operational focus.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• Dr. David L. Bear (person) — Appointed Chief Medical Officer
• Ms. Sarah P. Empey (person) — Elected to Board of Directors
• June 21, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $150,000 — pany's Executive Chair was decreased to $150,000; the annual salary for Trent Smith, the
• $285,000 — ief Financial Officer, was increased to $285,000; and the annual salary for Landy Toth,
• $137,500 — ief Technology Officer was decreased to $137,500; (ii) the following cash bonuses for t
• $74,250 — arch 31, 2024 - $150,000; Trent Smith - $74,250, the Company's Chief Financial Officer;
• $35,000 — , the Company's Chief Medical Officer - $35,000; and (iii) the following option grants
• $1 — of ten year, an exercise price equal to $1.3280, the 5-day average closing price o

Filing Documents

• amix20240621_8k.htm (8-K) — 26KB
• logo.jpg (GRAPHIC) — 2KB
• 0001437749-24-021003.txt ( ) — 166KB
• amix-20240621.xsd (EX-101.SCH) — 3KB
• amix-20240621_def.xml (EX-101.DEF) — 12KB
• amix-20240621_lab.xml (EX-101.LAB) — 15KB
• amix-20240621_pre.xml (EX-101.PRE) — 12KB
• amix20240621_8k_htm.xml (XML) — 3KB

From the Filing

amix20240621_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 ___________________________ Autonomix Medical, Inc. (Exact name of registrant as specified in its charter) ___________________________ Delaware 001-41940 47-1607810 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 21 Waterway Avenue, Suite 300 The Woodlands , TX 77380 (Address of principal executive offices) (Zip Code) Registrant ' s telephone number, including area code: ( 713 ) 588-6150 Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 21, 2024, the Compensation Committee (the " Committee ") of the Board of Directors (" Board ") of Autonomix Medical, Inc. (the "Company") approved the following compensation items: (i) the annual salary for Walter Klemp, the Company's Executive Chair was decreased to $150,000; the annual salary for Trent Smith, the Company's Chief Financial Officer, was increased to $285,000; and the annual salary for Landy Toth, the Company's Chief Technology Officer was decreased to $137,500; (ii) the following cash bonuses for the fiscal year ended March 31, 2024 were approved: Lori Bisson, the Company's Chief Executive Officer and President during the fiscal year ended March 31, 2024 - $150,000; Trent Smith - $74,250, the Company's Chief Financial Officer; and Dr. Robert Schwartz, the Company's Chief Medical Officer - $35,000; and (iii) the following option grants for the fiscal year ended March 31, 2024 were approved (each option had a term of ten year, an exercise price equal to $1.3280, the 5-day average closing price of our common stock as of June 20, 2024, and vest in four equal annual installments: Lori Bisson – option to purchase 377,221 shares; Walter Klemp – option to purchase 175,452 shares; Trent Smith – option to purchase 228,087 shares; Robert Schwartz – option to purchase 263,178 shares; and Landy Toth– option to purchase 175,452 shares. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: June 21, 2024

View Full Filing

View this 8-K filing on SEC EDGAR